Inactivation of the serpin alpha(2)-antiplasmin by stromelysin-1 - PubMed (original) (raw)
Inactivation of the serpin alpha(2)-antiplasmin by stromelysin-1
H R Lijnen et al. Biochim Biophys Acta. 2001.
Abstract
Matrix metalloproteinase-3 (MMP-3 or stromelysin-1) hydrolyzes the Met(374)-Ser(375) (P3-P2), Glu(416)-Leu(417) and Ser(432)-Leu(433) peptide bonds in human alpha(2)-antiplasmin (alpha(2)-AP), the main physiological plasmin inhibitor. Cleavage is completely abolished in the presence of the MMP inhibitors EDTA or 1,10-phenanthroline. At enzyme/substrate ratio of 1:10 at 37 degrees C, alpha(2)-AP protein cleavage occurs with a half-life of 8 min, and is associated with rapid loss of inhibitory activity towards plasmin with a half-life of 5 min. alpha(2)-AP cleaved by MMP-3 does no longer form a stable complex with plasmin, as shown by SDS-PAGE, and does no longer interact with plasminogen, as shown by crossed immunoelectrophoresis with plasminogen added to the gel. These data are compatible with the removal of a COOH-terminal fragment containing the reactive site peptide bond and the plasmin(ogen)-binding site. In addition, MMP-3 cleaves the Pro(19)-Leu(20) peptide bond in alpha(2)-AP, thereby removing the fibrin-binding site from the inhibitor. A dysfunctional alpha(2)-AP variant (Ala-alpha(2)-AP or alpha(2)-AP Enschede), with an alanine insertion in the reactive site sequence converting it from a plasmin inhibitor into a substrate, was also efficiently cleaved by MMP-3 (half-life of 13 min at 37 degrees C and enzyme/substrate ratio of 1:10). Cleavage and inactivation of alpha(2)-AP by MMP-3 may constitute a mechanism favoring local plasmin-mediated proteolysis.
Similar articles
- Matrix metalloproteinases and cellular fibrinolytic activity.
Lijnen HR. Lijnen HR. Biochemistry (Mosc). 2002 Jan;67(1):92-8. doi: 10.1023/a:1013908332232. Biochemistry (Mosc). 2002. PMID: 11841344 Review. - alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.
Kluft C, Nieuwenhuis HK, Rijken DC, Groeneveld E, Wijngaards G, van Berkel W, Dooijewaard G, Sixma JJ. Kluft C, et al. J Clin Invest. 1987 Nov;80(5):1391-400. doi: 10.1172/JCI113217. J Clin Invest. 1987. PMID: 2445779 Free PMC article. - Alpha 2-antiplasmin Enschede is not an inhibitor, but a substrate, of plasmin.
Rijken DC, Groeneveld E, Kluft C, Nieuwenhuis HK. Rijken DC, et al. Biochem J. 1988 Oct 15;255(2):609-15. Biochem J. 1988. PMID: 2974279 Free PMC article. - Natural heterogeneity of α2-antiplasmin: functional and clinical consequences.
Abdul S, Leebeek FW, Rijken DC, Uitte de Willige S. Abdul S, et al. Blood. 2016 Feb 4;127(5):538-45. doi: 10.1182/blood-2015-09-670117. Epub 2015 Dec 1. Blood. 2016. PMID: 26626994 Review.
Cited by
- Plasmin Inhibitor in Health and Diabetes: Role of the Protein as a Therapeutic Target.
Alsayejh B, Kietsiriroje N, Almutairi M, Simmons K, Pechlivani N, Ponnambalam S, Ajjan RA. Alsayejh B, et al. TH Open. 2022 Nov 18;6(4):e396-e407. doi: 10.1055/a-1957-6817. eCollection 2022 Oct. TH Open. 2022. PMID: 36452200 Free PMC article. Review. - α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis.
Kanno Y, Shu E. Kanno Y, et al. Life (Basel). 2022 Mar 9;12(3):396. doi: 10.3390/life12030396. Life (Basel). 2022. PMID: 35330147 Free PMC article. Review. - Serpins in cartilage and osteoarthritis: what do we know?
Wilkinson DJ. Wilkinson DJ. Biochem Soc Trans. 2021 Apr 30;49(2):1013-1026. doi: 10.1042/BST20201231. Biochem Soc Trans. 2021. PMID: 33843993 Free PMC article. Review. - Moonlighting matrix metalloproteinase substrates: Enhancement of proinflammatory functions of extracellular tyrosyl-tRNA synthetase upon cleavage.
Jobin PG, Solis N, Machado Y, Bell PA, Rai SK, Kwon NH, Kim S, Overall CM, Butler GS. Jobin PG, et al. J Biol Chem. 2020 Feb 21;295(8):2186-2202. doi: 10.1074/jbc.RA119.010486. Epub 2019 Nov 26. J Biol Chem. 2020. PMID: 31771979 Free PMC article. - Serine proteinases in the turnover of the cartilage extracellular matrix in the joint: implications for therapeutics.
Wilkinson DJ, Arques MDC, Huesa C, Rowan AD. Wilkinson DJ, et al. Br J Pharmacol. 2019 Jan;176(1):38-51. doi: 10.1111/bph.14173. Epub 2018 Mar 30. Br J Pharmacol. 2019. PMID: 29473950 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous